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Abstract
The human-animal bond has been a fundamental feature of mankind’s history for millennia. The first, and strongest
of these, man’s relationship with the dog, is believed to pre-date even agriculture, going back as far as 30,000
years. It remains at least as powerful today. Fed by the changing nature of the interactions between people and
their dogs worldwide and the increasing tendency towards close domesticity, the health of dogs has never played
a more important role in family life. Thanks to developments in scientific understanding and diagnostic techniques,
as well as changing priorities of pet owners, veterinarians are now able, and indeed expected, to play a
fundamental role in the prevention and treatment of canine disease, including canine vector-borne diseases
(CVBDs).
The CVBDs represent a varied and complex group of diseases, including anaplasmosis, babesiosis, bartonellosis,
borreliosis, dirofilariosis, ehrlichiosis, leishmaniosis, rickettsiosis and thelaziosis, with new syndromes being
uncovered every year. Many of these diseases can cause serious, even life-threatening clinical conditions in dogs,
with a number having zoonotic potential, affecting the human population.
Today, CVBDs pose a growing global threat as they continue their spread far from their traditional geographical
and temporal restraints as a result of changes in both climatic conditions and pet dog travel patterns, exposing
new populations to previously unknown infectious agents and posing unprecedented challenges to veterinarians.
In response to this growing threat, the CVBD World Forum, a multidisciplinary group of experts in CVBDs from
around the world which meets on an annual basis, gathered in Nice (France) in 2011 to share the latest research
on CVBDs and discuss the best approaches to managing these diseases around the world.
As a result of these discussions, we, the members of the CVBD Forum have developed the following
recommendations to veterinarians for the management of CVBDs.
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1. Forget about ‘exotic disease’: Veterinarians should
understand that the concept of ‘exotic’ diseases is no
longer applicable - any disease can appear in your prac-
tice, wherever you are based, and it is your responsibility
to maintain a working knowledge of these diseases, cur-
rent local and regional vector trends and threats asso-
ciated with client travel destinations, in order to ensure
accurate diagnosis.
2. Stay abreast of latest research: Research efforts in
the field are continually discovering new CVBDs, and
new information about existing CVBDs. Again, it is the
duty of the veterinarian to remain abreast of these
developments.
3. Prevention is the best approach: Prevention of
transmission is the best method of management for
CVBDs. Fortunately, we know that there are a limited
number of vectors involved - ticks, fleas, sand flies and
mosquitoes - and preventative parasiticides are available
either by chemoprophylaxis against the agent itself (as
in dirofilariosis) or against the ectoparasite vectors.
Veterinarians should be aware that pathogen transmis-
sion can occur almost immediately from the bites of
fleas, sand flies and in some cases from ticks. Therefore,
repellency is an important concept as preventative strat-
egy to avoid a blood meal by the arthropod vectors. As
a result of the changes in distribution of vectors, along
with increasing frequency of pet travel, it is also vital to
look to protecting pets from as many vectors as possi-
ble. This applies even in areas where some of these vec-
tors are not traditionally endemic. Furthermore, changes
in lifestyle and climate also mean that it is advisable to
ensure that protection, and tick and flea control in par-
ticular, is maintained year round.
4. Fleas are more than just a nuisance: Fleas have
been found to be vectors of a number of CVBDs and
tapeworm, but are often overlooked risk factors com-
pared with ticks, sand flies and mosquitoes. Flea preven-
tion is just as important as protection from other vectors
from both a veterinary and public health perspective.
5. Sand flies are the only proven vector of leishma-
niosis, but in non-endemic areas vets should be
aware of non-vectorial routes of transmission: While
sand flies are the only proven vector for leishmaniosis,
in rare cases the organism could potentially also be
transmitted by other routes (as e.g. vertical or venereal
transmission, or blood transfusion). As a result, espe-
cially in non-endemic areas, leishmaniosis should still be
considered as a potential diagnosis if there is a possibi-
lity of non-vectorial transmission from an exposed dog.
6. K n o wt h et r a v e ls c h e d u l eo fy o u rc l i e n t s :While
any dog can be affected, particular attention should be
paid to the health of dogs that travel or are imported
from other regions or are in contact with travelling
dogs. These dogs are at risk themselves, but also poten-
tially pose a threat to the health of local animals.
7. As diagnosis can be complex and challenging,
consider all options: Diagnosis of CVBDs is complex as
there are often no specific clinical signs and clinic-patho-
logical abnormalities, varied presentations and the pre-
sence in many cases of asymptomatic infection, posing a
hidden risk to the dog of future emergent diseases. It is
also important to consider possible co-infections, as
these are common, and can lead to complex manifesta-
tions and challenging diagnoses. When selecting diagnos-
tic procedures, alongside ensuring the use of scientifically
agreed standards, it may be necessary to combine multi-
ple tests in order to rule out infection/co-infections.
8. Understand that treatment may not be the end
of the story: Once diagnosed, treatment of CVBDs is
often challenging, in part due to the lack of effective
treatments, and the difficulty in achieving full elimina-
tion of the pathogen from the animal, even when
achieving a ‘clinical cure’. As a result, treated dogs can
remain as ‘Trojan horse’ reservoirs of disease for dogs
or other animals in the vicinity, and should therefore be
treated with preventative compounds to minimise the
risk of pathogen transmission by the competent vectors.
9. Engage with your clients to improve outcomes:
Routine, regular client education through delivery of the
annual health check is an essential aspect of veterinary
practice, and ensuring clients understand their role in
managing routine parasiticide use, vector exposure and
reporting signs is critical to an effective CVBD manage-
ment programme.
10. Alert public health authorities where appropri-
ate: Veterinarians are at the forefront of efforts to man-
age the risk of zoonotic disease. When treating animals
with CVBDs, remember that they may act as sentinels
for disease in the human population, and where appro-
priate, ensure local health authorities are notified. Veter-
inarians have a vital role to play in the ‘One Health’
approach to prevention of infectious disease.
In conclusion, we believe that while CVBDs are a
growing threat to the health of dogs worldwide, it is
within the power of veterinarians and pet owners to
manage this threat through the use of effective preventa-
tive treatments, education and awareness. We call on all
veterinarians wherever they are based to implement rig-
orous CVBD management programmes based on the
principles outlined abovet om a k ei tag l o b a la n dt h u s
effective strategy to reduce the burden of CVBDs.
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